17126-67-9

Basic information

• Product Name: (R)-2-Phenyl-3-hydroxypropionic acid
• Synonyms: (R)-2-Phenyl-3-hydroxypropionic acid;[R,(+)]-3-Hydroxy-2-phenylpropionic acid;D-Tropic acid
• CAS NO: 17126-67-9
• Molecular Formula: C₉H₁₀O₃
• Molecular Weight: 166.17
• Mol File: 17126-67-9.mol
• Article Data: 13

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• Solubility: Acetone (Sparingly), DMSO (Sparingly), Methanol (Slightly)
• CAS DataBase Reference: (R)-2-Phenyl-3-hydroxypropionic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-2-Phenyl-3-hydroxypropionic acid(17126-67-9)
• EPA Substance Registry System: (R)-2-Phenyl-3-hydroxypropionic acid(17126-67-9)

Safety Data

• Hazardous Substances Data: 17126-67-9(Hazardous Substances Data)

Usage

General Description

(R)-2-Phenyl-3-hydroxypropionic acid, also known as mandelic acid, is a chiral aromatic alpha hydroxy acid. It is a colorless, crystalline solid with a slight characteristic odor. Mandelic acid is primarily used in the synthesis of various pharmaceuticals and agrochemicals due to its pharmacological properties and ability to form stable complexes with metal ions. It is also commonly utilized in cosmetic products as an exfoliant and skin-brightening agent. Additionally, mandelic acid has demonstrated antibacterial and antiviral activities, making it a potentially useful ingredient in topical skincare formulations for treating acne and other skin conditions.

Upstream product

• 104266-89-9 (S)-4-benzyl-3-phenylacetyl-2-oxazolidinone 
• 110230-69-8 (S)-1-acetoxy-3-hydroxy-2-phenylpropane 
• 98017-92-6 2-phenyl-1,3-propanediol diacetate 
• 1570-95-2 2-phenylpropane-1, 3-diol 
• 204851-46-7 (S)-4-tert-butyl-3-(2'-phenylacetyl)oxazolidin-2-one 
• 529-64-6 Tropic acid 
• 131682-38-7 (+)-3-acetoxy-2-phenylpropionic acid 
• 3967-53-1 methyl tropate 

Downstream Products

• 32174-44-0 (2R)-methyl tropinate 
• 105539-05-7 (-)-(S)-2-(diethylamino)ethyl 2-phenyl-3-(tosyloxy)propanoate 
• 105538-99-6 (+)-(R)-2-(diethylamino)ethyl 2-phenyl-3-(tosyloxy)propanoate 
• 165260-55-9 (2R,3'S)-α-(Hydroxymethyl)benzeneacetic acid 1-azabicyclo<2.2.2>oct-3-yl ester 
• 165260-55-9 (2R,3'R)-α-(Hydroxymethyl)benzeneacetic acid 1-azabicyclo<2.2.2>oct-3-yl ester 
• 51-55-8 atropine 
• 105539-02-4 2-(diethylamino)ethyl (R)-(+)-tropate 
• 177567-33-8 Acetic acid (R)-2-(ethyl-pyridin-4-ylmethyl-carbamoyl)-2-phenyl-ethyl ester 
• 92934-63-9 R-(+)-tropicamide 
• 90319-52-1 (4R)-phenyl-2-oxazolidinone 
• 131682-38-7 (+)-3-acetoxy-2-phenylpropionic acid 
• 105539-04-6 2-(diethylamino)ethyl (S)-(-)-tropate 
• 65189-78-8 (-)-2-phenyl-2-carboxyethyl ester of 1-p-chlorobenzoyl-5-methoxy-2-methyl-3-indolylacetic acid 
• 65189-78-8 (+)-2-phenyl-2-carboxyethyl ester of 1-p-chlorobenzoyl-5-methoxy-2-methyl-3-indolylacetic acid 

Relevant articles and documents

PYRROLIDINE-PYRAZOLES AS PYRUVATE KINASE ACTIVATORS

The subject matter described herein is directed to pyruvate kinase activating compounds of Formula I and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds and methods of administering the compounds for the treatment of diseases associated with PKR and/or PKM2, such as pyruvate kinase deficiency, sickle cell disease, and beta-thalassemia.

SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS

Provided herein are compounds of the General Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, D, E, X1, X2, X3 and X4 have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including diseases or disorders mediated by a RET kinase.

High-performance liquid chromatography separation of enantiomers of mandelic acid and its analogs on a chiral stationary phase

The enantiomers of mandelic acid and its analogs have been chromatographically separated on a chiral stationary phase (CSP) derived from 4-(3,5-dinitrobenzamido) tetrahydrophenanthrene. The rationale of separations of these compounds is discussed with respect to the method development for determining enantiomeric purity and possibility of obtaining enantiomerically pure materials by high-pressure liquid chromatography. The relationship of analyte structure to the extent of enantiomeric separation has been examined and separation factors (a) are presented for various groups of structurally related compounds. Chiral recognition models have been suggested to account for the observed separations. These models provide mechanistic insights into the chiral recognition process.